Physician profile
Imran Umer
NPI 1780939660
$8,209.86
in general payments reported to CMS, 2019-2025
22 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,294 · 2020: $1,311 · 2021: $2,157 · 2022: $2,108 · 2023: $840 · 2024: $378 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,239 · Education: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,239.13 |
| Education | $100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,098.67 | 2019-2024 | Tavneos, Enbrel, Otezla |
| Abbvie INC. | $1,612.77 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $777.87 | 2019-2023 | Simponi Aria, Simponi, Remicade |
| Novartis Pharmaceuticals Corporation | $638.99 | 2019-2023 | |
| Ucb, INC. | $517.35 | 2019-2023 | Cimzia |
| Pfizer INC. | $470.52 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $397.13 | 2021-2023 | Acthar |
| Aurinia Pharma U.S., INC. | $335.66 | 2021-2023 | Lupkynis |
| Regeneron Healthcare Solutions, INC. | $278.98 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $277.61 | 2019-2022 | |
| Glaxosmithkline, LLC. | $263.57 | 2019-2023 | Benlysta |
| Genzyme Corporation | $179.27 | 2020-2023 | |
| Alexion Pharmaceuticals, INC. | $114.27 | 2022-2024 | Ultomiris |
| Lilly USA, LLC | $75.81 | 2022-2023 | Taltz, Olumiant |
| Mallinckrodt Enterprises LLC | $50.72 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $22.19 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.39 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $18.12 | 2021 | |
| Medtronic, INC. | $17.45 | 2022 | |
| Hikma Pharmaceuticals USA | $16.50 | 2019 | |
| Fresenius Kabi USA, LLC | $14.71 | 2023 | Idacio |
| Novo Nordisk INC | $12.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imran Umer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.